Stockscreener 앱 받기
14.92
0.86%
-0.13
시간 외 거래:
14.92
전일 마감가:
$15.05
열려 있는:
$14.87
하루 거래량:
1.20M
Relative Volume:
1.04
시가총액:
$1.53B
수익:
$83.98M
순이익/손실:
$-264.46M
주가수익비율:
-4.9045
EPS:
-3.0421
순현금흐름:
$-263.47M
1주 성능:
-4.42%
1개월 성능:
-5.51%
6개월 성능:
+76.78%
1년 성능:
+7.34%
1일 변동 폭
$14.60
$15.41
1주일 범위
$14.60
$16.11
52주 변동 폭
$8.18
$22.50
누릭스 테라퓨틱스 Stock (NRIX) Company Profile
명칭
Nurix Therapeutics Inc
전화
(415) 660-5320
주소
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
14.92 | 1.55B | 83.98M | -264.46M | -263.47M | -3.0421 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
누릭스 테라퓨틱스 Stock (NRIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-03-17 | 개시 | Leerink Partners | Market Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-11 | 개시 | Jefferies | Buy |
| 2024-09-06 | 재개 | Robert W. Baird | Outperform |
| 2024-07-31 | 개시 | Truist | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-09 | 개시 | Barclays | Overweight |
| 2023-02-28 | 개시 | Oppenheimer | Outperform |
| 2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-12-29 | 개시 | H.C. Wainwright | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-30 | 재개 | Piper Sandler | Overweight |
| 2021-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-11-19 | 개시 | Robert W. Baird | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
| 2020-08-18 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | Stifel | Buy |
모두보기
누릭스 테라퓨틱스 주식(NRIX)의 최신 뉴스
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - AOL.com
Investment Recap: Is Nurix Therapeutics Inc undervalued by DCF analysisGap Up & Low Drawdown Trading Techniques - baoquankhu1.vn
Cinctive Capital Management LP Raises Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Short Squeeze: Can Nurix Therapeutics Inc grow without external fundingWeekly Stock Summary & Community Verified Trade Signals - baoquankhu1.vn
Nurix Therapeutics, Inc. $NRIX Stake Cut by Commodore Capital LP - MarketBeat
Gains Report: Should I buy Nurix Therapeutics Inc stock now2026 Short Interest & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Surprises Report: Can Oak Woods Acquisition Corporation Equity Right disrupt its industry2026 Snapshot & Pattern Based Trade Signal System - baoquankhu1.vn
A Look At Nurix Therapeutics (NRIX) Valuation After Expanded Equity Distribution Agreement - Sahm
Understanding Momentum Shifts in (NRIX) - Stock Traders Daily
Market Moves: Will Nurix Therapeutics Inc announce a stock splitPortfolio Value Summary & Verified Technical Trade Signals - baoquankhu1.vn
Rhenman & Partners Asset Management AB Purchases 162,500 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Can Nurix Therapeutics Inc scale operations efficiently2025 Earnings Impact & Stepwise Trade Signal Guides - baoquankhu1.vn
Nurix Therapeutics Expands ATM Equity Offering Capacity - The Globe and Mail
Is Nurix Therapeutics Inc. stock a top momentum playJuly 2025 Levels & Scalable Portfolio Growth Ideas - Naître et grandir
Nurix Therapeutics amends equity distribution agreement for $413.65 million stock offering - Investing.com
Nurix Therapeutics adds $413.65M at-the-market equity facility with Piper Sandler - TradingView
Inflation Data: Whats the RSI of Nurix Therapeutics Inc stockPortfolio Value Report & Safe Investment Capital Preservation Plans - baoquankhu1.vn
ARK Investment Management LLC Has $13.96 Million Position in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics, Inc. $NRIX Stock Position Increased by Amova Asset Management Americas Inc. - MarketBeat
NRIX SEC FilingsNurix Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Handelsbanken Fonder AB Buys 240,000 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX) - GuruFocus
Planned stock sale by Nurix (NRIX) chief legal officer disclosed - Stock Titan
Christine Ring sells RSU shares (NRIX) under 10b5-1 plan via Morgan Stanley - Stock Titan
Buybacks Report: What are Calix Incs growth levers2025 Bull vs Bear & AI Based Trade Execution Alerts - baoquankhu1.vn
Nurix Therapeutics (NRIX) Valuation Check After Recent Share Price Volatility And Rich Price To Sales Multiple - Yahoo Finance
NRIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Avoiding Lag: Real-Time Signals in (NRIX) Movement - Stock Traders Daily
NRIX PE Ratio & Valuation, Is NRIX Overvalued - Intellectia AI
Redmile Group Increases Nurix Therapeutics Stake by 4.4M Shares - Intellectia AI
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - The Motley Fool
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Is There a 90% Upside Potential on the Horizon? - DirectorsTalk Interviews
Baker Bros discloses 7.2% Nurix (NRIX) ownership stake - Stock Titan
NRIX Technical Analysis & ETF Price Forecast - Intellectia AI
Discipline and Rules-Based Execution in NRIX Response - Stock Traders Daily
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Nurix Therapeutics Highlights STAT6, BTK and IRAK4 Degraders as Immunology Pipeline Gains Spotlight - MarketBeat
Does Nurix Therapeutics Inc. have a sustainable dividendJuly 2025 Institutional & Entry Point Confirmation Signals - mfd.ru
Is Nurix Therapeutics Inc. undervalued by DCF analysisQuarterly Portfolio Report & Accurate Entry/Exit Alerts - mfd.ru
What is the long term forecast for Nurix Therapeutics Inc. stockEarnings Summary Report & Reliable Trade Execution Plans - mfd.ru
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Emerging Potential With 90% Upside - DirectorsTalk Interviews
NRIX: Degrader therapies advance in immunology, with key milestones expected for STAT6 and BTK programs - TradingView
Why Nurix Therapeutics Inc. stock remains resilient2025 Earnings Impact & Daily Technical Stock Forecast Reports - mfd.ru
Nurix (NASDAQ: NRIX) CFO awarded 93,750 options and 42,875 RSUs - Stock Titan
Ring Christine, chief legal officer at Nurix, sells $237k in NRIX stock - Investing.com Canada
Assessing Nurix Therapeutics (NRIX) Valuation After Revenue Growth Wider Loss And New Shelf Registration - simplywall.st
HC Wainwright remains a buy on Nurix Therapeutics (NRIX) - MSN
Nurix Therapeutics (NRIX) Is Down 7.4% After Pivotal Bexobrutideg Update and Wider 2025 Loss - Sahm
VIX Spike: Can Nurix Therapeutics Inc sustain its profitabilityGDP Growth & Weekly High Return Stock Forecasts - baoquankhu1.vn
Nurix Therapeutics (NRIX) Is Down 7.4% After Wider 2025 Losses And New ESOP Share ShelfWhat's Changed - Yahoo Finance
누릭스 테라퓨틱스 (NRIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):